Zomedica Corp. [AMEX: ZOM] stock went on a downward path that fall over -7.89% on Monday, amounting to a one-week price decrease of less than -18.29%. The company report on February 16, 2021 that Zomedica Corp. Announces Full Exercise of Over-Allotment Option by Underwriter.
Zomedica Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that the underwriter of its previously announced public offering of has exercised in full its over-allotment option to purchase an additional 13,697,368 common shares of Zomedica at a price to the public of $1.90 per share, less underwriting discounts and commissions. After giving effect to the full exercise of the over-allotment option, the gross proceeds are approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Zomedica.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
H.C. Wainwright & Co. acted as the sole book-running manager for the offering.
Over the last 12 months, ZOM stock rose by 577.42%. The one-year Zomedica Corp. stock forecast points to a potential downside of -75.0. The average equity rating for ZOM stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.90 billion, with 550.54 million shares outstanding and 525.98 million shares in the current float. Compared to the average trading volume of 175.76M shares, ZOM stock reached a trading volume of 55659849 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Zomedica Corp. [ZOM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ZOM shares is $1.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ZOM stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Zomedica Corp. is set at 0.28 The Price to Book ratio for the last quarter was 26.25, with the Price to Cash per share for the same quarter was set at 0.06.
ZOM Stock Performance Analysis:
Zomedica Corp. [ZOM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -18.29. With this latest performance, ZOM shares gained by 110.00% in over the last four-week period, additionally plugging by 1446.39% over the last 6 months – not to mention a rise of 577.42% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 60.16, with the RSI for the last a single of trading hit 54.95, and the three-weeks RSI is set at 62.70 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 1.00, while it was recorded at 2.26 for the last single week of trading, and 0.36 for the last 200 days.
Insight into Zomedica Corp. Fundamentals:
Return on Total Capital for ZOM is now -687.86, given the latest momentum, and Return on Invested Capital for the company is -687.85. Return on Equity for this stock declined to -687.85, with Return on Assets sitting at -387.30.
Reflecting on the efficiency of the workforce at the company, Zomedica Corp. [ZOM] managed to generate an average of -$706,573 per employee.Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 25.60 and a Current Ratio set at 25.60.
ZOM Stock EPS
With the latest financial reports released by the company, Zomedica Corp. posted -0.03/share EPS, while the average EPS was predicted by analysts to be reported at -0.02/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -50.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZOM.
Zomedica Corp. [ZOM] Insider Position Details
There are presently around $101 million, or 6.80% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 19,340,445, which is approximately 79.474% of the company’s market cap and around 4.42% of the total institutional ownership; CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC., holding 12,254,080 shares of the stock with an approximate value of $25.73 million in ZOM stocks shares; and BLACKROCK INC., currently with $17.76 million in ZOM stock with ownership of nearly New of the company’s market capitalization.
Positions in Zomedica Corp. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 22 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 20,252,520 shares. Additionally, 17 investors decreased positions by around 4,856,670 shares, while 6 investors held positions by with 22,921,707 shares. The mentioned changes placed institutional holdings at 48,030,897 shares, according to the latest SEC report filing. ZOM stock had 14 new institutional investments in for a total of 9,006,014 shares, while 10 institutional investors sold positions of 1,398,017 shares during the same period.